| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
Allergen immunotherapy has been established as a treatment of type I allergy. However, it remains a critical concern for their allergic side effects, including anaphylaxis. The purpose of this study is to develop more effective and safe immunotherapeutic agents. As the results, we prepared the allergenicity reducing OVA glycated with heparin and found that ferulic acid and its glycosides showed higher TGF-beta stimulating activity. Further, oral administration of glycated OVA and ferulic acid rutinoside resulted in the suppression of allergic responses and induction of Tregs in OVA-sensitized mice. The present findings should contribute to the development of immunomodulatory agents for the prevention and treatment of food allergy.
|
